Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, April 14, 2017 1:25:13 PM
by Eric Sagonowsky | Feb 21, 2017 4:30pm
http://www.fiercepharma.com/vaccines/flu-vaccines-48-effective-so-far-season-cdc-says
So far this season, flu vaccines have been 48% effective in preventing medical visits, according to a CDC estimate.
This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season. But, as of data ending Feb. 4, government experts don’t expect the season to come to a close right away.
CDC anticipates “several more weeks” of flu activity in parts of the U.S., according to an agency update. So far, vaccines have been 48% effective in preventing flu-related medical visits, the CDC estimates.
That compares to 59% for last year and 19% for the year before, according to the CDC. Over 10 previous flu seasons, vaccine effectiveness has fluctuated each year, often ending up with a percentage in the 40s or 50s.
Separately this year, CDC experts recommended against any use of AstraZeneca’s FluMist on efficacy concerns from three previous seasons. AZ said it’s working to assess the situation.
All year round, experts monitor the virus and select strains for the upcoming season. But, in an effort to improve on so-so efficacy and avoid strain drift, several biopharma companies are working on “universal” vaccines that fight a range of strains over multiple years.
Sanofi, the world’s largest flu vaccine manufacturer, in late 2015 unveiled its work in the area. It announced a vax project dubbed Cobra that’s designed to protect against multiple strains by using common sequences the strains share.
Other companies and groups that have gotten into universal flu vaccine work include Johnson & Johnson’s Crucell and Scripps Research Institute, plus biotechs BiondVax and FluGen.
Recent BVXV News
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2024 08:06:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2024 09:27:06 PM
- Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/12/2024 08:17:13 PM
- Scinai leadership to attend BIO-Europe Spring 2024 • PR Newswire (US) • 03/12/2024 12:00:00 PM
- Scinai Welcomes Liat Halpert as Head of Business Development and Sales • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds • PR Newswire (US) • 01/04/2024 09:01:00 PM
- Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule • PR Newswire (US) • 11/20/2023 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM